Status:
RECRUITING
A 2-Part Study to Learn Whether Litifilimab (BIIB059) Injections Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus
Lead Sponsor:
Biogen
Conditions:
Subacute Cutaneous Lupus Erythematosus
Chronic Cutaneous Lupus Erythematosus
Eligibility:
All Genders
18+ years
Phase:
PHASE2
PHASE3
Detailed Description
Litifilimab is a humanized immunoglobulin G1 (IgG1) monoclonal antibody targeting blood dendritic cell antigen 2. It is an inhibitory receptor expressed on the surface of human plasmacytoid dendritic ...
Eligibility Criteria
No eligibility criteria provided.
Key Trial Info
Start Date :
September 13 2022
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 14 2027
Estimated Enrollment :
450 Patients enrolled
Trial Details
Trial ID
NCT05531565
Start Date
September 13 2022
End Date
December 14 2027
Last Update
March 12 2026
Active Locations (305)
Enter a location and click search to find clinical trials sorted by distance.
1
Pinnacle Research Group, LLC
Anniston, Alabama, United States, 36207
2
UAB Center for Women's Reproductive Health
Birmingham, Alabama, United States, 35233-7340
3
Arizona Arthritis & Rheumatology Research, PLLC
Phoenix, Arizona, United States, 85032
4
The Regents of the University of California
La Jolla, California, United States, 92037